BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 21843519)

  • 1. Measurement of NT-proBNP with LOCI technology in heart failure patients.
    Gruson D; Ahn SA; Lepoutre T; Rousseau MF
    Clin Biochem; 2012 Jan; 45(1-2):171-4. PubMed ID: 21843519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and methods of the Pro-B Type Natriuretic Peptide Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) Study.
    Bhardwaj A; Rehman SU; Mohammed A; Baggish AL; Moore SA; Januzzi JL
    Am Heart J; 2010 Apr; 159(4):532-538.e1. PubMed ID: 20362709
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NT-proBNP in monitoring treatment of patients with congestive heart failure.
    Al-Meslmani BM; Fahoum SK; Shamia MG
    Clin Lab; 2007; 53(1-2):35-9. PubMed ID: 17323823
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hemoglobin and N-terminal pro-brain natriuretic peptide: Independent and synergistic predictors of mortality in patients with acute heart failure Results from the International Collaborative of NT-proBNP (ICON) Study.
    Baggish AL; van Kimmenade R; Bayes-Genis A; Davis M; Lainchbury JG; Frampton C; Pinto Y; Richards MA; Januzzi JL
    Clin Chim Acta; 2007 Jun; 381(2):145-50. PubMed ID: 17445789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Comparison study on diagnostic and prognostic value of N-terminal probrain natriuretic peptide and atrium natriuretic peptide in chronic congestive heart failure].
    Dong H; Chen DQ; Wang Y; Li M
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 Aug; 28(9):1740-2. PubMed ID: 18819908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Changes of serum N-terminal pro-brain natriuretic peptide levels in patients with cardiovascular diseases and its clinical significance].
    Yang CL; Qiu YR; Zhou F; Feng PF
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 May; 28(5):866-9. PubMed ID: 18504223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure.
    von Haehling S; Jankowska EA; Morgenthaler NG; Vassanelli C; Zanolla L; Rozentryt P; Filippatos GS; Doehner W; Koehler F; Papassotiriou J; Kremastinos DT; Banasiak W; Struck J; Ponikowski P; Bergmann A; Anker SD
    J Am Coll Cardiol; 2007 Nov; 50(20):1973-80. PubMed ID: 17996563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serial NT-proBNP monitoring and outcomes in outpatients with decompensation of heart failure.
    Bayes-Genis A; Pascual-Figal D; Fabregat J; Domingo M; Planas F; Casas T; Ordoñez-Llanos J; Valdes M; Cinca J
    Int J Cardiol; 2007 Sep; 120(3):338-43. PubMed ID: 17174423
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serial testing of B-type natriuretic peptide and NTpro-BNP for monitoring therapy of heart failure: the role of biologic variation in the interpretation of results.
    Wu AH
    Am Heart J; 2006 Nov; 152(5):828-34. PubMed ID: 17070141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of atrial fibrillation and amino-terminal pro-brain natriuretic peptide concentrations in dyspneic subjects with and without acute heart failure: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) study.
    Morello A; Lloyd-Jones DM; Chae CU; van Kimmenade RR; Chen AC; Baggish AL; O'Donoghue M; Lee-Lewandrowski E; Januzzi JL
    Am Heart J; 2007 Jan; 153(1):90-7. PubMed ID: 17174644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multi-center validation of the Response Biomedical Corporation RAMP NT-proBNP assay with comparison to the Roche Diagnostics GmbH Elecsys proBNP assay.
    Lee-Lewandrowski E; Januzzi JL; Green SM; Tannous B; Wu AH; Smith A; Wong A; Murakami MM; Kaczmarek J; Apple FS; Miller WL; Hartman K; Jaffe AS
    Clin Chim Acta; 2007; 386(1-2):20-4. PubMed ID: 17854790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Diagnostic value of NT-proBNP in identifying aortic stenosis patients with heart failure].
    Wu C; Yang YJ; Zhao XY; Zhang J; Huang J; Wei BQ; Sun HS; Wang W; Yan P
    Zhonghua Xin Xue Guan Bing Za Zhi; 2010 Jul; 38(7):579-83. PubMed ID: 21055276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Changes in NT-proBNP levels in patients with atrial fibrillation related to heart failure].
    Pokorná V; Jurkovicová O; Kaluzay J; Stecová A; Pont'uch P
    Vnitr Lek; 2010 Aug; 56(8):788-94. PubMed ID: 20845610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparing serum and pleural fluid pro-brain natriuretic peptide (NT-proBNP) levels with pleural-to-serum albumin gradient for the identification of cardiac effusions misclassified by Light's criteria.
    Porcel JM; Chorda J; Cao G; Esquerda A; Ruiz-González A; Vives M
    Respirology; 2007 Sep; 12(5):654-9. PubMed ID: 17875051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. N-terminal pro-brain natriuretic peptide testing in the emergency department: beneficial effects on hospitalization, costs, and outcome.
    Rutten JH; Steyerberg EW; Boomsma F; van Saase JL; Deckers JW; Hoogsteden HC; Lindemans J; van den Meiracker AH
    Am Heart J; 2008 Jul; 156(1):71-7. PubMed ID: 18585499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Usefulness and predictive value of circulating NT-proBNP levels to stratify patients for referral and priority treatment in a specialized outpatient heart failure center.
    Amir O; Paz H; Ammar R; Yaniv N; Schliamser JE; Lewis BS
    Isr Med Assoc J; 2008 Feb; 10(2):109-12. PubMed ID: 18432021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study.
    Januzzi JL; van Kimmenade R; Lainchbury J; Bayes-Genis A; Ordonez-Llanos J; Santalo-Bel M; Pinto YM; Richards M
    Eur Heart J; 2006 Feb; 27(3):330-7. PubMed ID: 16293638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of changes in N-terminal pro-brain natriuretic peptide in Val-HeFT (Valsartan Heart Failure Trial).
    Masson S; Latini R; Anand IS; Barlera S; Angelici L; Vago T; Tognoni G; Cohn JN;
    J Am Coll Cardiol; 2008 Sep; 52(12):997-1003. PubMed ID: 18786480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Amino-terminal pro-brain natriuretic peptide and brain natriuretic peptide measurements under various detection conditions in patients with chronic heart failure].
    Wang WJ; Zhang XM; Wang Q; Wen DM; Ouyang NL; Cui YL; Li F
    Zhonghua Xin Xue Guan Bing Za Zhi; 2011 Aug; 39(8):695-9. PubMed ID: 22169413
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The relationship between N-terminal pro-brain natriuretic peptide and risk for hospitalization and mortality is curvilinear in patients with chronic heart failure.
    Schou M; Gustafsson F; Corell P; Kistorp CN; Kjaer A; Hildebrandt PR
    Am Heart J; 2007 Jul; 154(1):123-9. PubMed ID: 17584564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.